JP2010099041A - Recombinant measles virus useful as bivalent vaccine for measles and malaria infection - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To provide a vaccine safe and effective against malaria infections, and a vector used for producing the vaccine, and to further provide a bivalent vaccine exhibiting excellent protective effects on measles virus and the malaria infections, and eliminating complicatedness during inoculation. <P>SOLUTION: A recombinant measles virus in which a gene encoding a protein associated with onset protection against the malaria infections is inserted into a measles virus genome is provided. The protein associated with the onset protection against the malaria infections is preferably selected from among pfEMP-1, MAEBL, AMA-1, MSP-1, LSA-1, Pfs230 etc. Furthermore, there is provided the bivalent vaccine for the measles and malaria infections containing the recombinant measles virus, and even an antiserum obtained from a body fluid collected from an animal infected with the recombinant measles virus. In addition, there is provided a method for producing the vaccine for the malaria infections including using the measles virus as the vaccine vector in producing the vaccine for the malaria infections. <P>COPYRIGHT: (C)2010,JPO&INPIT

Description

  The present invention relates to a recombinant measles virus having a vaccine action against measles and malaria infection, a vaccine containing the same, and an antiserum obtained therefrom.

  Malaria is an infectious disease caused by Plasmodium, a genus Protozoan genus Plasmodium plus module genus. The World Health Organization (WHO) makes malaria three major infectious diseases along with AIDS and tuberculosis. Each year, 300 million to 500 million people are ill, and 1 million to 3 million people die, mainly in the tropics and subtropics. Over 90% of the outbreaks occur in sub-Saharan Africa, but it is prevalent in over 100 countries around the world, and 40% (2.3 billion) of the world population is said to be at risk of infection. In Asia, outbreaks have been reported in southern China, the Philippines, Vietnam, Laos, Thailand, Cambodia, Myanmar, Indonesia and Malaysia. In recent years, with global warming, malaria is expected to expand the infected area. In addition, an increase in the number of cases that develop after returning home from malaria is also a problem.

  Malaria parasites are characterized by parasitic in the cells of other animals among parasites, and the hosts are reptiles, birds, and mammals in vertebrates, and do not infest fish and amphibians. Malaria parasites that infect humans include 1) Plasmodium falciparum, 2) Plasmodium vivax, 3) Plasmodium ovale, and 4) Plasmodium malaria. There are four species of protozoa (Plasmosium malariae), but Plasmodium falciparum accounts for the majority of infections and has the highest lethality.

  Human infection is mediated by Anopheles and is caused by malaria parasite infestation. Symptoms may be high fever, headache, joint pain, become severe without proper treatment, fall into a coma and eventually die.

  To date, attempts have been made to combat malaria by 1) measures against anopheles using insecticides, 2) prevention and treatment using drugs, but due to the emergence of insecticide-resistant anopheles and drug resistance against malaria parasites, it is currently effective. No specific method has been found. In addition, vaccines against malaria have been developed for a long time, but no effective vaccines have been developed yet.

  Although malaria parasites are mediated by mosquitoes, it is necessary to understand the life history of malaria when considering vaccines. In other words, 1) The time when an anopheles female infected with malaria parasite bites a human and injects the malaria parasite (sporozoite) into the blood vessel (several minutes), 2) the malaria parasite enters the liver, and in the liver cells When to proliferate (1 to 2 weeks) 3) When hepatocytes are ruptured, merozoites are released into the blood, invade red blood cells, proliferate again, and newly born protozoa invade more red blood cells (this time 4) Four stages of time (10-14 days) when the mosquito sucks blood from this patient and the protozoa grows on the stomach wall of the mosquito and injects with saliva when the mosquito sucks another person It is. When considering vaccines that suppress the growth of malaria and promote healing in humans, 1) to 3) of the above are the targets.

  In addition, the immune reaction at each stage must be considered 1) neutralizing antibody 2) cellular immunity 3) antibody that prevents entry into red blood cells. Anti-sporozoite vaccines and anti-merozoite vaccines have been proposed based on these stages in the life history of malaria parasites, but due to the clever mechanism that avoids the human immune system of malaria parasites, all vaccines It is not effective in actually preventing malaria infection.

  Among the vaccines proposed so far, there are vaccines that identify various antigenic epitopes of malaria and use these peptides and DNA vaccines that contain DNA encoding these peptides. . In addition, the DNA vaccine has the disadvantages that it may cause an autoimmune disease by induction of anti-DNA antibodies, and the antigen will be expressed permanently.

  Measles, on the other hand, was the most well-known common childhood disease until recently. Clinical features include prodromal symptoms such as fever, nasal discharge, and conjunctivitis, followed by a rash on the head and then spread to the chest, trunk, and extremities. It often causes complications such as otitis media, krupp, bronchitis, bronchiolitis. When undernourished children die from measles, the cause of death is usually bacterial pneumonia. However, the most dangerous measles complication is acute infectious encephalopathy, which occurs at a rate of about 1 per 1,000 cases of measles, with a mortality rate of about 15%. Remains.

  In countries where vaccinations are not so common, major outbreaks are repeated every few years, with many outbreaks occurring mainly from late autumn to spring. In the United States, the measles vaccine was approved in 1963, but before that, the epidemic repeated every few years, and 500,000 cases of measles were reported annually and about 500 measles deaths occurred in the year of the epidemic. Has been reported. Since 1963, reports of measles patients have declined sharply, and no major epidemic has been seen every few years. In 1983, the number of measles patients decreased to 1,497 a year.

  However, mortality from childhood measles within the first year of life is high in developing countries, and the World Health Organization (WHO) has implemented vaccination as a priority and part of extended vaccination. In these areas, maternal antibody decline is more rapid than in developed countries, and children are more susceptible to measles early on, so the death of undernourished children is a major cause of childhood death. One of them.

  Measles is caused by measles virus classified as Paramyxoviridae and Morbillivirus. Viral particles have a polymorphic elliptical structure and are 100-250 nm in diameter. The inner capsid has a helical negative RNA genome, and the outer envelope has a matrix protein, hemagglutinin (H) protein, and a short surface glycoprotein (M) protrusion of the fusion (F) protein. H and F proteins are necessary for viral cell adsorption and cell fusion, and M protein is necessary for viral assembly. There are six structural proteins and one non-structural protein as viral proteins.

As a vaccine against measles, a live vaccine in which measles virus is subcultured in cell culture and attenuated is used, and the effect of immunity is prolonged.
However, the idea of using measles virus as a vector for malaria vaccine has never been seen.

  As described above, an effective vaccine against malaria infection has not been put into practical use. Accordingly, an object of the present invention is to provide a safe and effective vaccine against malaria infection and a vector used for the production of such a vaccine. Furthermore, the objective of this invention is providing the bivalent vaccine which exhibited the outstanding protective effect with respect to the measles virus and the malaria infection, and also the complexity at the time of inoculation was eliminated.

  The inventors of the present invention, while studying the development of an effective malaria vaccine, paid attention to the production of a vaccine using a viral vaccine vector, and obtained the idea of using measles virus as a vector in the process. Since measles virus has been established as a live vaccine, its safety and effectiveness have been established, so it can be used as a virus vaccine vector in terms of inducing an effective immune response and providing lifelong immunity. We attempted to create a recombinant measles virus by inserting a gene encoding a protective antigen against malaria parasites. As a result of intensive studies, the present inventors have found that the recombinant measles virus thus obtained can stably express the malaria parasite infection protective antigen gene, which is an inserted foreign gene, in infected cells, It was found that it can be used as a viral vector. That is, a recombinant measles virus useful as a vaccine against measles and malaria could be obtained.

Therefore, the gist of the present invention resides in a recombinant measles virus in which a gene encoding a protein involved in defense against malaria infection is inserted into the measles virus genome.
In addition, the present invention is a recombinant measles virus having a transmission ability capable of expressing a protein that provides protection against malaria infection after inoculation in living cells.

In the above, the protein involved in the defense against malaria infection is preferably selected from pfEMP-1, MAEBL, AMA-1, MSP-1, LSA-1, Pfs230, and the like.
Furthermore, the present invention also relates to the above-mentioned recombinant measles virus, characterized in that one or more measles virus genomic genes, particularly measles virus functional protein genes are modified.

  The recombinant measles virus may include a foreign gene other than a gene encoding a protein involved in the defense against malaria infection, for example, an antigen recognition site gene of a monoclonal antibody against a cancer-specific marker molecule.

  Furthermore, according to the present invention, the present invention also relates to an RNA contained in the recombinant measles virus and a DNA containing a template cDNA capable of transcribing the recombinant measles virus genomic RNA. This DNA is preferably in the form of a plasmid.

  The present invention also relates to a bivalent vaccine against measles and malaria infection, including the recombinant measles virus. Further, the present invention relates to an antiserum obtained from a body fluid collected from an animal infected with the recombinant measles virus. Also provided is a method for producing a vaccine against malaria infection, characterized in that measles virus is used as a vaccine vector in the production of a vaccine against malaria infection.

  As described above, according to the present invention, it is possible to provide a vaccine against malaria infection that has been difficult to put into practical use until now, and the protection against measles and malaria infection is a single recombinant. This is possible with the measles virus vaccine. In addition, antisera against malaria infection enables diagnosis and treatment of malaria.

Hereinafter, the recombinant measles virus of the present invention and a vaccine containing the same will be described in detail.
In the present invention, measles virus is used as a vaccine vector in the production of a vaccine against malaria infection. That is, a recombinant measles virus in which a gene encoding a protein involved in defense against malaria infection is inserted into the measles virus genome and used as a vaccine.

  For the production of the recombinant measles virus of the present invention, for example, a reverse genetic system used for reconstitution of canine distemper virus described in JP-A-2001-275684 can be used. Since genetic manipulations such as modification of the viral genome and introduction of foreign genes are carried out at the DNA level, it is necessary to obtain viral genomic cDNA for genetic manipulation of measles virus belonging to the (-)-strand RNA virus. That is, it is necessary to reconstitute recombinant measles virus particles having a transmission power via cDNA. More specifically, a cDNA of measles virus genomic RNA is obtained, and a desired foreign gene is incorporated therein to obtain a recombinant cDNA. Measles virus particles can be reconstituted by introducing this cDNA into a cell expressing a gene related to transcriptional replication together with a unit capable of transcribing RNA in the cell using this cDNA as a template.

  The measles virus used for the production of the recombinant measles virus may be any measles virus capable of inducing a high neutralizing antibody against the field epidemic measles virus, and examples thereof include HL strain and ICB strain. Alternatively, a vaccine strain such as an Edmonston strain can be used as long as it has been genetically modified to induce production of the relevant neutralizing antibody.

  The malaria parasite gene inserted into the measles virus genome as a foreign gene may be any gene that encodes a protein that provides protection against malaria disease. For example, it encodes a protein related to the pathogenicity and proliferation of the malaria parasite. There are genes that can generate an immune response when expressed in vivo. As a protein that protects against malaria, various antigens have been found in various stages of the life history of the malaria parasite, and one or more antigens in any one of these stages, or two or more A gene encoding each antigen in the stage can be used. Examples of such genes include, but are not limited to:

pfEMP-1: Infected erythrocyte surface antigen (U31083)
MAEBL: Rhoptryprotein (AF400002)
AMA1: Apical membrane antigen-1 (M27133)
MSP-1: Asexual blood stage merozoite surface protein-1 (M19143)
LSA1: Liver stage antigen (Z30319, Z30320, X56203)
Pfs230: Maternal surface protein (L08135)
In the above, parentheses are DBJ registration numbers.

  The base sequences of these genes have been determined. For example, the base sequences of the pfEMP-1 gene and the MAEBL gene are also described in the databases GenBank AF286005 and AY042084, respectively. Using primers and RNA extracted from Plasmodium, pfEMP-1 gene and MAEBL gene cDNA can be obtained.

  The measles virus genome has a leader sequence and a trailer sequence involved in virus replication at both ends, and has N, P, M, F, H, and L genes encoding viral constituent proteins therebetween. N protein binds to viral RNA in order from the 3 'end and is packaged. Three types of proteins, P protein, V protein, and C protein, are produced from the P gene, and it has been revealed that the P protein is involved in viral transcription and replication as a small subunit of RNA polymerase. The L protein functions as a large subunit of RNA polymerase. The M protein supports the virus particle structure from the inside, and the F protein and the H protein are involved in invasion into the host cell.

  In order to produce the recombinant measles virus of the present invention, first, genomic RNA is prepared from the measles virus as described above, and its cDNA is produced. cDNA is connected downstream of a specific promoter, and genomic RNA or cRNA is transcribed depending on the direction of cDNA connection. The cDNA of the malaria parasite gene described above is inserted into this cDNA by genetic engineering to produce a recombinant cDNA.

  In the production of the recombinant measles virus of the present invention, the site for inserting the gene encoding the protective antigen for malaria in the measles virus genome is not particularly limited, but N, P, M, F, H, and L It can be inserted between each gene of the gene and upstream of the N gene.

  When preparing the measles virus genome cDNA, restriction enzyme recognition sequences are appropriately placed between and at both ends of the N, P, M, F, H, and L genes encoding the proteins constituting the virus. Therefore, it is possible to easily insert a target foreign gene and to select a site exhibiting the optimal expression of the foreign protein. As a specific example in which a restriction enzyme recognition sequence is arranged between each gene, for example, there is plasmid pMV (7+) used in Example 1 (see FIG. 1).

  As long as the recombinant measles virus of the present invention is effective in protecting against infection with malaria parasite and retains transmission ability, even if any other foreign gene is inserted at any site of RNA contained in the recombinant, Any genomic gene may be deleted or modified. Other foreign genes to be inserted include genes encoding various proteins that induce pathogenicity in viruses, bacteria and parasites that can be expressed in the host, genes encoding various cytokines, and genes encoding various peptide hormones. And a gene encoding an antigen recognition site in the antibody molecule. For example, there are influenza virus, mumps virus, HIV, dengue virus, diphtheria, leishmania, etc. and antigen recognition site genes of monoclonal antibodies against cancer-specific marker molecules. The expression level of the inserted foreign gene can be controlled by the position of gene insertion or the RNA base sequence before and after the gene. In addition, for example, in order to inactivate genes involved in immunogenicity or increase RNA transcription efficiency or replication efficiency, some genes involved in RNA replication of measles virus may be modified. Specifically, the intervening sequence and the leader part are modified.

  A host that expresses all of the measles virus or related virus transcription and replication enzymes, together with a unit that can transcribe RNA in the cell using the cDNA of the measles virus genome that has been genetically manipulated as described above. A recombinant virus can be produced by introduction into The unit capable of transcribing RNA is, for example, DNA expressing a DNA-dependent RNA polymerase that acts on a specific promoter, and the cDNA subjected to the above-described genetic manipulation is connected downstream of this specific promoter. Specific examples of this unit include, for example, a recombinant vaccinia virus that expresses T7 RNA polymerase, and a cultured cell in which a T7 RNA polymerase gene is artificially incorporated.

  The host into which the cDNA is introduced together with this unit is a host that expresses all of the measles virus or closely related virus transcriptase group, that is, N protein, P protein and L protein, or a protein having the same activity as these. Any host can be used. For example, cells having genes encoding these proteins on the chromosome may be used, or plasmids having genes encoding N protein, P protein, and L protein may be appropriately introduced into the cells. Preferably, 293 cells or B95a cells introduced with appropriate plasmids having N gene, P gene and L gene can be used.

  The recombinant measles virus of the present invention obtained as described above contains a gene encoding a protein that provides malaria onset protection, and this gene is a recombinant virus as demonstrated in the following examples. Since the protein that protects against the onset of malaria disease is expressed in infected cells after inoculation, it exerts the effect of preventing the growth of malaria parasites. Moreover, since this recombinant virus maintains its function as a measles virus, it is also effective as a vaccine against measles.

  The vaccine of the present invention can be produced by mixing the recombinant measles virus of the present invention with a pharmaceutically acceptable carrier and appropriate additives as required by a method usually used in this field. Pharmaceutically acceptable carriers are diluents, excipients, binders that do not cause adverse physiological reactions to the subject of administration and do not adversely interact with other components of the vaccine composition, Examples of the solvent include water, physiological saline, and various buffer solutions. Additives that can be used include adjuvants, stabilizers, tonicity agents, buffers, solubilizers, suspending agents, preservatives, antifreezing agents, cryoprotectants, freeze-drying agents, bacteriostatic agents, etc. Illustrated.

  The dosage form of the vaccine may be liquid, frozen or lyophilized. A liquid vaccine can be produced by appropriately collecting a culture solution obtained by culturing in a culture medium, cultured cells, etc., adding an additive such as a stabilizer and dispensing the solution into small jars or ampoules. . After dispensing, the product is frozen by gradually lowering the temperature, which is a frozen vaccine, and a freezing damage prevention agent or a freezing protection agent is added in advance. The dispensed container is frozen in a freeze-dryer and then vacuum-dried, and the freeze-dried vaccine can be obtained by directly filling with nitrogen gas and sealing tightly. Liquid vaccines are used as they are or diluted with physiological saline or the like. For frozen and dried vaccines, a solution for dissolving the vaccine at the time of use is used. The solution for dissolution is various buffers or physiological saline.

  As adjuvants for enhancing immunogenicity, those commonly used in this field can be used.For example, BCG, cells such as Propionibacterium acnes, cell walls, cell components such as trehalose dimycolate (TDM), gram-negative bacteria Origin of lipopolysaccharide (LPS), lipid A fraction, β-glucan, N-acetylmuramyl dipeptide (MDP), synthetic compounds such as pestatin, levamisole, and other biological components such as thymic hormone, thymic factor, and tuftsin Examples thereof include proteins, peptide substances, Freund's incomplete adjuvant, Freund's complete adjuvant, and the like.

The vaccine can be administered by subcutaneous administration, intramuscular administration, intravenous administration, and the like. The dose varies depending on the subject's age, weight, sex, administration method, etc., and is not particularly limited. However, the dose is usually preferably 10 ⁴ to 10 ⁷ TCID ₅₀ , particularly at least 10 ⁵ TCID _50. preferable. Administration is preferably performed in the same manner as the measles vaccine.

It is also possible to infect animals with the above-mentioned recombinant measles virus, obtain antisera from body fluids, and use it for treatment and diagnosis.
The present invention will be specifically described by the following examples, but the present invention is not limited to these examples.

Production of recombinant measles virus with pfEMP gene (MV-pfEMP) The infectious cDNA clone required for the production of recombinant MV is based on the genome sequence of measles virus field strain HL and is a protein that constitutes the virus. PMV (7+) prepared by artificially placing a restriction enzyme recognition sequence at both ends of 6 genes encoding the gene (Fig. 1) was used.

  The pfEMP CIDR-1 region cDNA, a erythrocyte surface antigen of malaria parasite, was obtained by RT-PCR using total RNA extracted from the malaria parasite (FCR-3 strain). pfEMP cDNA was amplified again with a primer (SEQ ID NO: 1 and 2) to which an FseI restriction enzyme recognition sequence was added, cloned into a plasmid vector, and the nucleotide sequence was examined. The pfEMP cDNA obtained by digesting this plasmid with FseI is inserted into the FseI site between the N and P genes of pMV (7+), and an infectious cDNA clone pMV- that produces a recombinant measles virus having the pfEMP gene. got pfEMP. Fig. 2 shows a simple construction diagram of pMV-pfEMP.

(Primer sequence)
Sequence number 1: 5'-tat agg ccg gccatc att gttata aaa aactta gga acc agg ttc atccac aat gcatcc ttt tttttg gaa gtg-3 '
Sequence number 2: 5'-tgt cgg ccg gcccta cta tgttgg tgg tgattg ttt gt-3 '
The reconstitution experiment of the recombinant measles virus was performed as follows.

  A normal trypsin-treated 293 cell was added to a 6-well plate, 1,000,000 cells per well and 2 ml of DMEM medium containing 5% bovine extermination serum were added, and cultured for 24 hours under conditions of 5% CO2 and 37 ° C. Remove the culture medium and add to the well a suspension of recombinant vaccinia virus MVA-T7 expressing T7 RNA polymerase adjusted to a moi (multiplicity of infection) of 2 in 0.2 ml of PBS. did. The plate was shaken so that the virus solution spread throughout the well every 10 minutes and infected for 1 hour. After 1 hour, the virus solution was removed, 2 ml of medium was added to each well, and then 100 μl of cDNA solution was added dropwise. The cDNA solution was prepared as follows.

  Place 1 μg, 1 μg, and 0.1 μg of plasmids pGEM-NP, pGEM-P, and pGEM-L, which are required for measles virus replication, in a 1.5 ml sampling tube, and pMV (7 +)-pfEMP-1 10 μl of nucleic acid solution was prepared by adding μg and sterilized distilled water. In another sampling tube, 0.08 ml of DMEM medium was prepared, 10 μl of Fugene 6 (Roche Diagnostics) was added dropwise thereto, and then allowed to stand at room temperature for 5 minutes in this state. This was mixed with a nucleic acid solution and allowed to stand at room temperature for 15 minutes or longer to obtain a cDNA solution.

The plate containing the wells was cultured for 3 days under conditions of 5% CO 2 and 37 ° C. On day 3, the medium was removed, and B95a cells suspended in RPMI-1640 medium containing 5% fetal calf serum were added to 1,000,000 cells per well and overlaid on 293 cells. The plate was further cultured under conditions of 5% CO 2 and 37 ° C. until a cytotoxic effect (CPE) was observed.
The production of recombinant measles virus (MV-pfEMP) was confirmed by RT-PCR and sequencing.

Confirmation of pfEMP expression in recombinant measles virus (MV-pfEMP) infected cells
B95a cells were infected with MV-pfEMP1, and after 48 hours the cells were fixed with 4% paraformaldehyde and permeabilized with 0.2% TritonX-100. 1000-fold diluted anti-pfEMP1 antibody (rabbit serum) was added and allowed to react for 1 hour at room temperature. After removing the pfEMP1 antibody and washing 3 times with PBS, the FITC-labeled anti-rabbit IgG antibody was diluted 2000 times and added, and reacted at room temperature for 30 minutes. After removing the anti-rabbit IgG antibody and washing 5 times with PBS, the infected cells were observed using a confocal laser microscope. As a result, FITC fluorescence was observed only in MV-pfEMP1-infected cells, confirming the expression of the pfEMP1 antigen (FIG. 3).

It is a figure which shows the outline of preparation of pMV-HL (7+). It is a figure which shows the outline of preparation of pMV-pfEMP. It is a figure which shows the expression of pfEMP in a recombinant measles virus (MV-pfEMP) infection cell.

Claims (11)

  A recombinant measles virus in which a gene encoding a protein involved in the prevention of malaria infection is inserted into the measles virus genome.   A recombinant measles virus capable of expressing a protein that protects against the onset of malaria infection after inoculation in living cells.   The protein involved in the onset prevention of malaria infection is at least one selected from the group consisting of pfEMP-1, MAEBL, AMA-1, MSP-1, LSA-1, and Pfs230. The recombinant measles virus described.   The recombinant measles virus according to any one of claims 1 to 3, wherein one or more measles virus genomic genes are modified.   The recombinant measles virus according to any one of claims 1 to 4, further comprising a foreign gene other than a gene encoding a protein relating to the onset defense of malaria infection.   RNA contained in the recombinant measles virus according to any one of claims 1 to 5.   A DNA comprising a template cDNA capable of transcribing the recombinant measles virus genomic RNA according to claim 6.   The DNA according to claim 7, which is in the form of a plasmid.   A bivalent vaccine against measles and malaria infection comprising the recombinant measles virus according to any one of claims 1 to 5 and a pharmaceutically acceptable carrier.   Antiserum obtained from a body fluid collected from an animal infected with the recombinant measles virus according to any one of claims 1 to 5.   A method for producing a vaccine against malaria infection, which comprises using a measles virus as a vaccine vector in the production of a vaccine against malaria infection.

Images